Myles HelfandExecutive Editor
Myles Helfand is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more—and accumulating an ever-growing mountain of HIV conference badges along the way.
Latest by Myles Helfand
July 29, 2021: Racial disparities in hospitalization rates; city-specific mortality demographics; effects of traditional risk factors vs. antiretrovirals on weight gain and cardiovascular risk.
July 22, 2021: How HIV criminalization laws may reduce disclosure; anxiety and housing satisfaction; poor immune response to delayed ART; the U.S.'s HIV testing mountain.
Our quick summaries of breaking conference research include new study findings on injectable long-acting cabotegravir/rilpivirine and the latest on lenacapavir, a twice-yearly injectable medication in the pipeline.
July 15, 2021: Mind existing drug interactions when switching ART; lamivudine dosing amidst renal impairment; HPV vaccination among MSM; cervical cancer screening for women with HIV.
July 8, 2021: Trends among heavily treatment-experienced PLWH; a new look at peripheral neuropathy factors; heart transplantation in PLWH; complications following successful HCV treatment.
June 24, 2021: Effect of efavirenz metabolism on weight change; determinants of weight gain when switching meds; metabolic effects of DTG vs. TAF; food security vs. nutrition security.
June 17, 2021: PrEP awareness vs. PrEP willingness among young Black women; acute HIV infection during PrEP initiation; real-world PrEP efficacy; HIV rates by U.S. region among transgender people.
The latest update to official guidelines issued by the U.S. Department of Health and Human Services occurred within the adult/adolescent guidelines on June 3.
June 10, 2021: Trauma, burden, and COVID-19 risk among PLWH; sleep and viral suppression; spirituality/religioisity, depression, and HIV risk; why anal cancer screening isn't enough.
June 3, 2021: Kaposi sarcoma despite ART; heat-based cervical HPV treatment; re-evaluating HIV-associated neurocognitive disorder; HIV and diabetes in Texas.